$3.27 Billion
The market capitalization is the market value of the company. It is the sum of the value of all outstanding shares.$16.3 Million
Total revenue in the last quarter.-$32.4 Million
Net income is all revenues minus all expenses including taxes and interest in the last quarter.-$2.30
Earnings per share is the amount of net income that is attributed to each single share outstanding.$0.00 (0.0%)
Dividends per share is the amount of dividends paid out to the shareholder of a single share in the last 12 months. The percentage indicates the ratio of the company's annual dividend compared to its current price per share (stock price).-28.19x
The price-earnings ratio is the ratio between the price per share (stock price) and the earnings per share. It indicates the percentage of the price per share (stock price) that is generated in earnings in the last 12 months.$-33 Million
Earnings before interest expenses and taxes in the last quarter.211
The number of full time employees.Intellia Therapeutics is a biotechnology company developing biopharmaceuticals using a CRISPR gene editing system invented by Jennifer Doudna and Virginijus Šikšnys . The company has partnerships with Novartis and Regeneron. Intellia Therapeutics was founded in May 2014 to develop biopharmaceuticals using CRISPR.
Raymond James Stick to Their Buy Rating for Intellia Therapeutics
The global CRISPR technology market reached a value of nearly $685.5 million in 2019, having increased at a compound annual growth rate (CAGR) of 35.0% since 2015. The market is expected to grow fr...
Intellia Therapeutics announce their quarterly, annual earnings. See the latest EPS estimates. Listen to the conference call and remind yourself by…
